Le texte complet de cet article est disponible en PDF.
This study reports the results with the longest radiographic follow-up of the new Surpass Evolve flow diverter.
Our results demonstrate encouraging technical success and good radiological outcomes.
Favorable aneurysm occlusion (O’Kelly Marotta grading scale C-D) at six month follow-up was achieved in 21/27 (78%) aneurysms.
Background and purpose
Several studies have reported good long-term results in the occlusion of intracranial aneurysms with flow diverter treatment. The aim of this study was to report the safety and six-month follow-up outcomes using the new Surpass Evolve flow diverter in the treatment of intracranial aneurysms.
Materials and methods
Consecutive patients with intracranial aneurysm treated with Surpass Evolve flow diverter in two high-volume neurovascular centers between May 2019 and January 2020 were retrospectively reviewed. Procedure-related complications, aneurysm occlusion (O’Kelly-Marotta grading scale), and clinical outcomes were assessed.
Twenty-nine patients with 30 aneurysms were included in the study. Favorable aneurysm occlusion (O’Kelly Marotta grading scale C-D) at six-month follow-up was achieved in 21/27 (78%) aneurysms. No clinical procedure related thromboembolic complications were encountered. Twenty-three out of 24 patients with unruptured aneurysms treated with Surpass Evolve remained clinically intact at clinical follow-up. There was one fatal hemorrhagic procedure-related complication (3%). In five patients with ruptured aneurysms, no early or late rebleeds occurred from the aneurysms.
Surpass Evolve FD worked technically well with no intraprocedural thromboembolic complications and occlusion rates comparable to other FDs.Le texte complet de cet article est disponible en PDF.
Keywords : Aneurysm, Intracranial, Endovascular, Flow diverter, Surpass Evolve
Abbreviations : ACT, FD, mRS, OKM